WHICH IS WHICH?!
GERD is a disease; dyspepsia is a symptom!
- GERD = symptoms or complications resulting from the reflux of gastric contents into the esophagus or beyond (e.g. oral cavity, larynx, lung)
- key literature: 2013 ACG guideline
- dyspepsia = nonspecific epigastric discomfort
- key literature: 2017 ACG/CAG guideline
GERD has many symptoms:
- typical: retrosternal burning (i.e. heartburn), regurgitation
- less common: cough, chest pain, sore throat
- atypical (may suggest overlapping condition): dyspepsia, nausea, bloating, belching
DDx for dyspepsia is extensive!
- common: functional dyspepsia, H.pylori infection, PUD, GERD, multiple meds (see below), gastric cancer
- meds: NSAIDs, CCB, methylxanthines, alendronate, orlistat, oral potassium, acarbose, dabigatran, iron, vitamin D, SSRI, sildenafil, sulfonylureas, and certain antibiotics, including erythromycin
- less common: biliary pain, gastroparesis, pancreatitis, malabsorption, infiltrative disease (e.g. Crohn’s), metabolic (e.g. hypercalcemia), ischemic bowel disease, celiac artery compression syndrome, SMA syndrome, systemic disorders (e.g. DM, thyroid/parathyroid disease), connective tissue disease, parasitic infection, other cancers (HCC, pancreatic cancer), etc
ALARM FEATURES!
Alarm features are similar for both GERD and dyspepsia, but the work-up differs!
- Alarm features:
- age of onset >60yo
- unintentional weight loss (>5-10% over 6-12 months)
- overt GI bleeding
- dysphagia or odynophagia
- unexplained iron deficiency anemia
- persistent vomiting or hematemesis
- palpable mass or lymphadenopathy
- family history of upper gastrointestinal cancer in first-degree relative
Work-up differences:
- GERD: endoscopy is generally recommended for adult pts in the presence of alarm features
- dyspepsia: endoscopy is generally not recommended in pts <60yo even in the presence of alarm symptoms because the risk of malignancy remains <1%; nevertheless, consider endoscopy in the presence of prominent alarm symptoms (e.g. significant weight loss or rapidly progressive dysphagia) and always on a case-by-case basis (i.e. lower threshold to perform endoscopy for alarm feature in 58yo pt vs 28yo pt)
- note: studies of alarm features have only looked at single features as opposed to combinations of them
H.PYLORI!
Key literature: 2017 ACG guideline
Variable prevalence: generally higher prevalence outside the US (especially in Asia, Africa, Central America, and South America)
Testing indications:
- definite: confirmed PUD, MALT lymphoma, dyspepsia, and s/p endoscopic resection of early gastric cancer
- less-established but recommended by ACG: unexplained iron deficiency anemia, ITP
- controversial: chronic NSAID/ASA use, first-degree FHx of gastric ca
- key point: GERD is not an indication for H.pylori testing
Diagnosis: fecal antigen test (sensitivity = 94%, specificity = 97%) or urea breath test (sensitivity = 88-95%, specificity = 95-100%)
- false negatives are common for both testing modalities in 3 situations: recent use of antibiotics/bismuth (must be off for 4wk), recent use of PPI (must be off for 1-2wk), or actively bleeding peptic ulcer
Treatment: triple therapy (avoid clarithromycin if pt has any prior macrolide use); otherwise quadruple therapy
- triple therapy = PPI BID + clarithromycin 500mg BID + amoxicillin 1000mg BID
- quadruple therapy = PPI BID + bismuth subsalicylate 300mg QID + metronidazole 500mg QID + tetracycline 500mg QID
Follow-up: eradication testing should be performed ≥4wk after completing initial treatment because ~25% of pts fail initial therapy